Postinflammatory hyperpigmentation - Hiperpigmentación Postinflamatoria
A Hiperpigmentación Postinflamatoria (Postinflammatory hyperpigmentation) é unha afección cutánea caracterizada polo aumento do pigmento na pel tras a inflamación da pel. A hiperpigmentación postinflamatoria (postinflammatory hyperpigmentation) pode ser causada pola exposición prolongada ao sol, unha inflamación ou outras lesións cutáneas, incluídas as relacionadas co acne. As persoas con tons de pel máis escuros adoitan ser máis propensas á hiperpigmentación con exceso de exposición ao sol.
☆ Nos resultados de Stiftung Warentest de Alemaña de 2022, a satisfacción dos consumidores con ModelDerm foi só lixeiramente inferior á das consultas de telemedicina pagas.
References
Postinflammatory hyperpigmentation (PIH) é un problema de pel frecuente que ocorre despois dunha inflamación ou danos na pel. Adoita durar moito tempo e é peor en persoas con tons de pel máis escuros (Fitzpatrick skin types III–VI) . Aínda que moitas veces mellora por si só, isto pode levar un tempo, polo que adoita ser necesario o tratamento durante moito tempo. A combinación de diferentes tratamentos funciona mellor.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation é unha secuela común da inflamación da pel. Tende a afectar ás persoas de pel máis escura de forma máis severa e frecuente. Os estudos demostran que problemas como postinflammatory hyperpigmentation están entre os principais motivos polos que as persoas con tons de pel máis escuros buscan coidados dermatolóxicos. O tratamento precoz é fundamental para resolver postinflammatory hyperpigmentation e normalmente comeza coa xestión da condición inflamatoria inicial. A primeira liña de tratamento normalmente implica o uso de axentes tópicos que iluminan a pel xunto con protector solar para a súa protección. Estes axentes, como hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , poden reducir eficazmente a pigmentación excesiva. Ademais, os retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy tamén se usan como axentes despigmentantes, e aparecen novos tratamentos. Aínda que os tratamentos tópicos adoitan ser efectivos para a hiperpigmentación a nivel de superficie, os procedementos (laser, chemical peel) poden ser necesarios para os casos teimudos. É importante ter coidado con estes tratamentos para evitar a irritación e o empeoramento de postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
